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Abstract … 160 …
This essay begins by proposing that muscle weakness of old age from sarcopenia is due
in large part to reduced capillary density in the muscles, as documented in 9 reports of aged
persons and animals. Capillary density (CD) is determined by local levels of various angiogenic
factors, which also decline in muscles with aging, as reported in 7 studies of old persons and
animals. There are also numerous reports of reduced CD in the aged brain and other studies
showing reduced CD in the kidney and heart of aged animals. Thus a waning angiogenesis
throughout the body may be a natural occurrence in later years and may account significantly for
the lesser ailments (physical and cognitive) of elderly people. Old age is regarded here as a
deficiency state which may be corrected by therapeutic angiogenesis, much as a hormonal
deficiency can be relieved by the appropriate hormone therapy. Such therapy could employ
recombinant angiogenic factors which are now commercially available.

Key Words: muscle weakness, sarcopenia, capillary density, angiogenesis, therapeutic
angiogenesis, deficiency state
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TEXT … 7229 … 5 06 15
1. Introduction
In the years before succumbing to a fatal illness (cardiovascular disease, malignancy,
pneumonia, etc.), most older persons complain of several lesser ailments – occasional memory
lapses/pauses (senior moments) and muscle weakness. I suggest that these symptoms of aging
may share a common pathology – i.e., a deficient microcirculation secondary to the age-linked
decline of angiogenic (AG) factors. Loss of muscle strength is the main focus of this essay,
while minor memory problems of old age are secondary here and akin to the more serious
cognitive decline (senile dementias) discussed in previous papers. Ambrose

2012, 2013, 2015A

The physical and mental deterioration characterizing old age has been ascribed to the
numerous causes. Comfort 12974, Hayflickl 1975, Kowald 1996, Weinert 2003, Duc 2014 In 1974, a reviewer
commented that there seems to be one theory on aging for every published investigator. Marx 1974
The various proposals have been considered under two broad groupings: developmental (genetic)
versus stochastic (random) … with specific theories falling under one group or sometimes under
both. It is now generally assumed that most cases of aging are due to several deleterious
influences. Correcting one of them might slow or moderate the general deterioration.
The various theories of aging (e.g., longevity gene, somatic mutations, epigenetic
modifications, stress, thymic atrophy, free radical toxicity, etc.) seem tenable but suggest no
concrete means of therapy … or at least any measures readily available for general use now.
However, practical therapeutic approaches are offered by theories which invoke a deficiency
state – e.g., hormonal levels falling with age. Another deficiency state is the age-linked decline
of angiogenic growth factors -- the major concern of this paper.
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By way of background for this essay, the microcirculation throughout the body is
commonly designated as capillary density (CD) and is determined in large part by local levels
of angiogenic (AG) factors – e.g., vascular endothelial growth factor (VEGF), fibroblastic
growth factor (FGF), and others. The brain will be discussed briefly first, because data showing
reduced CD there support the analogous reduction to be discussed later in muscles. As
documented in an earlier paper, reduced cerebral capillary density has been reported in the
brains of aged people (5 reports), those with Alzheimer’s disease (5 reports), and also old rats
and mice (13 reports). Ambrose 2015A:

Tables 2 & 3

See Footnote 1. These data led to the

Neuroangiogenesis Hypothesis (NAG hypothesis) advanced in that paper as one cause of
impaired cognition in persons with senile dementias.
The levels of angiogenic factors have not been reported in the brains of aged persons,
but one recent study found diminished levels of VEGF in the parietal cortex of old rats.
Viboolvorakul 2014

When specifically looked for, a comparable decline of AG factors in the aged

human brain may likely be found, consistent with the above report on rats and comparable to
lower levels in aged muscle -- as treated next. My review of levels of CD and AG factors in the
aging brain led to examining the literature for similar studies in the muscles of aged people and
animals, where depressed levels have indeed been found. This later review is the basis for
presenting here a view of age-linked muscle weakness which can be termed the MAAG
hypothesis (for muscle-associated angiogenesis) -- a corollary to the NAG hypothesis.
Muscle strength appears influenced directly not only by AG factors (via CD) but also by
muscle stem cells and both secondarily by certain hormones. The waning muscle mass in older
persons reflects the age-related decrease in progenitor stem cells, which are acted upon by
hormones (Section 3). Considerable data indicate that the age-associated falling levels of various
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hormones directly influence declining levels of AG factors in older persons (Section 4). Matrix
proteins (fibronectin, laminin, etc.) interacting with various growth factors may also affect
muscle stability/strength via angiogenesis. Arthur 1998,

Sadoun 2003

This essay has two parts: Part I concerns angiogenic factors, stem cells, and hormones in
the context of muscle weakness, while Part II suggests therapeutic options for relieving muscle
weakness with angiogenic agents. These are now commercially available in recombinant forms,
and their use would seem comparable to that of various hormones in their respective deficiency
states.

Part I: Decreased Angiogenesis in Muscles with Age
2. Muscle weakness and waning angiogenesis
In aged persons, muscle weakness and diminished exercise tolerance are commonly
ascribed to a failing heart and/or diseased lungs – i.e., to a reduced level of oxygenated blood
available to the body tissues. Wagner 2006 Atherosclerosis, strokes, injuries, and a sedentary life
style also lead to muscle weakness due to a reduced skeletal muscle mass, termed sarcopenia. In
the elderly this condition is more conspicuous in the legs than in the arms and trunk, perhaps
because the latter are being moved even when sitting. Borkan 1983: Table

2

Sarcopenia is defined as

“appendicular skeletal muscle mass … being less than two standard deviations below the mean
of a young reference group.” Baumgartner 1998 By age 80, in both sexes there is “a 30-50% decrease
in skeletal muscle mass” due to loss in number of muscle fibers. Faulkner 2007 Sarcopenia is
associated with reduced local CD and reduced levels of AG factors, as documented below.

2.1. Reduced CD and AG factors in skeletal muscles
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Five reports of reduced CD in lower limb muscles of elderly persons are presented in
Table 1. Four such studies in the skeletal muscles of aged laboratory animals are listed in Table
2. Lower levels of AG factors have been found in skeletal muscles of the aged – 4 reports in
aged people (Table 3) and 4 in old animals (Table 4). In animal muscle studies, experimental
support for role of VEGF in maintaining CD comes from two opposite approaches: suppressing
endogenous levels of VEGF or correcting low levels (enhancing angiogenesis) with exogenous
VEGF.

2.2. Suppressing angiogenesis with an antibody or an enzyme
Amaral et al. tested rats in which exercise training induced on three consecutive days was
shown to increase CD in skeletal muscles. Monoclonal VEGF neutralizing antibody was
injected intraperitoneally on Day -1, +1, & +2 of the 3-day exercise protocol. The CD (capillary
intersections/mm2) in the tibialis anterior muscle on Day 3 was 129 in the control rats and
reduced to 108 in the antibody-treated rats. A comparable decline was found in the
gastrocnemius muscle. Amaral

2001: Fig. 5

Several groups of investigators have depleted VEGF throughout the gastrocnemius
muscle of transgenic mice by the local injection of a recombinant cre recombinase adenoassociated viral vector. Tang

2004, Wagner 2006

Tang et al. found that this procedure reduced the

expression of three isoforms of VEGF in the injected muscles. Correspondingly, the local
capillary density was reduced to 64% by week 4 and was 69% on week 8.

2.3. Enhancing angiogenesis with recombinant VEGF
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The opposite approach has involved administering growth factors to animals and
measuring CD in leg muscles. Rivard et al. created hind limb ischemia in both old and young
rabbits, which were injected with recombinant VEGF on postoperative day 10 via the iliac artery
of the affected limb. On Day -10 (before injection) and Day 40 the average CDs (expressed as
capillaries/mm2) in young rabbits were 170 & 280 (64%) and in old rabbits were 130 & 190
(46%). Rivard 1999 Comparable results were obtained in similar experiments with mice.
While diminished local levels of AG factors and the resulting reduced CD may account
directly for muscle weakness and sarcopenia, other biological processes may also be involved –
e.g., a reduced presence of myogenic stem cells and diminished levels of various hormones.

3. Muscle weakness and waning muscle stem cells
In higher animals after birth, the maintenance and regeneration of skeletal muscles
involve tissue-specific stem cells – a.k.a., myogenic precursor cells, progenitor cells, or satellite
cells. Sieveking 2009 These reside adjacent to mature myocytes beneath the lambia propria and are
quiescent until activated by muscle injury or exercise. Either stimulus induces proliferation of
the precursor cells and formation of nascent myotubules. Conboy 2002 This activation is under
control of the Notch and related signaling pathways. (Footnote 2)
During old age, the regenerative capacity of muscle declines because the stem cells
become less activated via the Notch pathway. Conboy 2003,

Brack 2007, Carlson 2008

Discussion of it is

beyond the scope of this essay except for the following conclusion. The various pathways
responsible for muscle repair are regulated by “systemic factors” which change with age. Wagers
2005, ;l;;Conboy 2005

These factors were not specified but likely include hormones. For example,

Sinha-Hikim et al. found that testosterone administered to elderly men increased the number of
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muscle satellite cells. Sinha-Hikim 2006 Tateishi-Yuyama et al. “reported that the CD34-fraction of
bone marrow stem cells” synthesize VEGF, bFGF, and Ang-1. Tateishi-Yuyama 2002 Thus muscle
stem cells may provide paracrine AG factors in muscle areas.
Stem cells have been used therapeutically. Tateishi-Yuyama et al. implanted bone
marrow-mononuclear cells (including endothelial progenitor cells) into ischemic limbs of
persons with peripheral arterial disease and noted new collateral vessel formation, as disclosed in
angiograms. The subjects reported increased pain-free walking times and reduced leg rest pain.
Ischemic ulcers and gangrene were also lessened. Tateishi-Yuyama 2002

4. Muscle weakness and waning hormone levels
In a 1997 article entitled “The Endocrinology of Aging,” Lamberts et al. ascribed loss of
muscle strength in aged persons to diminished levels of various agents -- insulin, thyroxine, and
several other hormones: dehydroepiandrosterone, testosterone, estrogen, or growth
hormone/insulin-like GH. Lamberts 1997 Of these, testosterone, estrogen, and thyroxine will be
discussed below because of the abundant data showing that their actions on muscles and other
tissues involve angiogenesis.

4.1. Androgens
An association between androgens and angiogenesis has been found in the prostate, heart,
skeletal muscles, and brain of mice, rats, men, and even some song birds.
Castration of male mice resulted in a decreased VEGF content of ventral prostate tissue.
Joseph 1997

The prostates of adult rats injected with dehydrotestosterone (DHT) showed a “a four-

fold increase in VEGF specific activity.” Sordello 1998 Numerous papers have reported that
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androgens up-regulate VEGF in cultures of normal and malignant human prostatic cells. Joseph
1997, Sordello 1998, Eisermann 2013

In a rat model of myocardial infarction (ligation of a coronary artery), castration of males
impaired the expression of VEGF in the ischemic myocardium. Chen 2012a Here testosterone
replacement therapy promoted angiogenesis in the myocardium, as measured 28 days after
infarction. In a mouse hind limb ischemia model, castrated male mice showed a reduced CD in
the affected limb but a restored vacularization upon treatment with an androgen. Sieveking 2010 The
authors concluded that androgens exerted a proangiogenic effect which depends on VEGF and
involves the mobilization of angiogenic-progenitor cells to sites of ischemia. Sieveking 2009, 2010
In older men, exogenous testosterone increases skeletal muscle mass, thus reversing
sarcopenia. Uban 1995,

Bhasin 1996, Sih 1997, Snyder 1999, Ferrando 2002, Wittert 2003, Sinha-Hikim 2006, Atkinson 2010,

The seasonal acquisition of song capacity in some canaries and finches is related to rising
levels of testosterone, which trigger neuronal production in the higher vocal center (HVC). Chen
2013

This is preceded by a burst of local endothelial cell division and angiogenesis, as evidenced

by a rise in VEGF mRNA and VEGF protein. Cultures of canary HVC endothelial cell increased
their rate of division in response to VEGF but not to testosterone. This suggests that in the
brains of these birds testosterone induces the paracrine production of VEGF.

4.2. Estrogens
Morales et al. examined several human umbilical endothelial cell culture systems and
found that 17β-estradiol promoted migration and proliferation of the cells and formation of
capillary-like networks. Morales 1995 The authors wrote that estradiol “enhances the multiple
components of angiogenesis activity in vitro” and may augment the action of angiogenic growth
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factors in tissues with either high estrogenic content or abundant estrogen responsiveness. This
association may account for women having a higher incidence of various vasculitic diseases.
The effect of 17β-estradiol modulating angiogenesis was also studied by others. Rubanyi 2002

4.3. Thyroid hormones
These hormones induce neovascularization in various settings – muscles, the heart, brain,
and tumors. Luidens 2010, Zhang 2010 As outlined by Liu et al., the process begins for thyroid
hormones at cell surface receptors on endothelial and muscle cells (e.g., integrin αvβ3). The
hormone signal is transduced via this receptor for the transcription of angiogenic-relevant genes,
which leads to the synthesis and secretion of AG proteins. Liu 2014 Mousa et al. wrote that the
hormone and its analogues modulate the “activities of multiple vascular growth factors receptors
and their ligands” – thus linking this hormone to angiogenesis. Mousa 2014 Four experimental
examples of thyroid-related angiogenesis follow.
Heart failure (“cardiac microvascular impairment”) was produced in mice within a year
of being fed propylthiouracil (PTU) to make them hypothyroid.

Chen 2012

Triiodothyronine (T3)

administered for three day induced significant capillary growth in the heart.
The forebrain regions of thyroidectomized rats showed decreased CD. Thyroxine (T4) or
a thyroid analog “normalized” the blood vessel density. Schlenker 2008 Decreased brain
angiogenesis (a “reduced complexity and density of microvessels”) was found in young rats
treated with PTU for 21 days to induce hypothyroidism. Zhang 2010
The severe mental retardation in cretinism has generally been ascribed to the direct effect
of hypothyroidism on CNS neurons and myelination. Zhang 2010 But, as the above examples in rats
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suggest, the retardation might result primarily from a deficient cerebral angiogenesis and
secondarily from defective/deficient neurons.
In summary, the above studies raise the possibility that the deficiency of one or more
relevant hormones may lead to sarcopenia or otherwise impair function because of reduced
angiogenesis.

5. Enhanced Muscle strength and physiologic angiogenesis
Exercise induces increased CD and the release of AG factors in the muscles of people
and animals. Gavin 2007,

Lloyd 2003

See Table 5. This could be termed physiologic angiogenesis in

contrast to pharmacologic/therapeutic angiogenesis, discussed later in Part II. Such AG factors
may exert a beneficial paracrine effect on endothelial cells and perhaps on myogenic progenitor
cells and thus help reverse sarcopenia. Upon entering the circulation, the factors could stimulate
angiogenesis in distant sites – i.e., have an endocrine effect. Gerontologists have long
advocated walking to help maintain/improve mobility (muscle strength) and to benefit the
cardiovascular system -- possibly adding a year or so of life. Pafenbarger 1986
Educators have also encouraged walking, since this has been thought to enhance learning
in people and mice. Colcombe 2004,

van Praag 1999

A recent paper by Strothart et al. suggests that any

benefit in cognition from exercise may be a placebo effect, while an article by Hillman et al.
confirms “the importance of physical activity on mental development.” Strohart 2014, Hillman 2014
Exercise has an immediate effect of increasing circulation in the brain from vasodilatation, but it
may provide a long term effect by increasing cerebral capillary density. Isaacs et al. observed
increased angiogenesis in the rat cerebellum after it underwent vigorous physical activity. Isaacs
1992

Ding et al. reported that aged rats run daily for three weeks in a treadmill showed increased
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cerebral CD and elevation of VEGF mRNA ( 27%) and VEGF protein ( c.20%) in the motor
cortex and striatum.

Ding 2006: Fig. 4 & 6

Table 5A shows increased local CD and/or elevated levels of VEGF from 21 reports on
exercised muscles in people and animals. Human subjects (15 studies) exercised on a bicycle
ergometer or single leg extension device, while small animals (6) were run on a circular
treadmill. Table 5B shows 10 studies involving electrical stimulation with electrodes implanted
into the flexor muscle of one leg of a rat or rabbit. In both types of experiments, biopsies were
taken from the flexor muscles of animals or the vastus lateralis or other lower muscle of human
subjects. Experimental and control biopsies were examined for evidence of increased vascularity
(CD) and/or for levels of VEGF protein and VEGF mRNA. Representative of these studies on
human subjects are the four following reports – the first two showing increased CD in muscles
with exercise and the last two illustrating elevated muscle levels of VEGF with exercise.
Denis et al. examined two groups of men (G20: age 22 ±3 yrs and G60: age 62 ±4 yrs)
who trained for 20 weeks pedaling a bicycle ergometer at 75 rpm for 60 min/day, 4 times a week.
Needle biopsies were obtained from the vastus lateralis muscle before and after training.
Capillary density (cap/mm2) in the G20 group increased from 316 ±42 to 396 ±73 (25%). The
CD in the G60 group rose from 308 ±48 to 409 ±55 (32%). Denis 1986
Gavin et al. observed increased capillarization (“capillary contacts” = cc) and levels of
VEGF mRNA in the vastus lateralis in both young men (19-30 yrs) and old men (56-74 yrs)
after 8 weeks of aerobic exercise. Capillary density (cc/mm2) in young men rose from 264 ±16
to 341 ±29 (29%) and in old men from 303 ±28 to 350 ±63 (15%). Gavin 2007
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Richardson et al. subjected young males to the exercise stimulus of a single leg kneeextensor ergometer. Biopsies of vastus lateralis muscle revealed VEGF mRNA levels of 0.38

±0.04 before exercise and 7.1 ±1.8 one hour afterwards. Richardson 1999
Gustafsson et al. followed healthy males who underwent 8 weeks of a one-legged kneeextension program. One day after the 7th training session, muscle biopsies showed a two-fold
increase in both VEGF mRNA and VEGF protein expression. Gustafsson 2001, 2002
Relevant to this essay’s concern with aging is that the increased CD and elevated levels
of AG factors were often less in the challenged muscles of old animals and elderly people than
in those of their younger counterparts. For example, Adolfsson et al. found that exercise
increased CD in young rat muscles from a baseline value of 460  710 (54%) and in old rats
from 395  484 (23%). Adolfsson 1981 The same trend was found in several others reports,
including that of Gavin et al above, where the young human subjects showed a 29% increase and
the elderly only a 15% increase. Coggan 1992, Ryan 2006, Gavin 2007.

6. Summary of Part I and an Overview of Angiogenesis in Muscles during Aging
The above review from the literature on muscle physiology is the basis of the muscleassociated angiogenesis hypothesis. Tables 1 & 2 of this essay present data from 9 reports
showing that CD declines in the skeletal muscles of both people and animals with age. These
reports are complemented by similar data from other areas of the body. In a previous publication
are summarized 18 studies showing reduced CD in the aged brains of people and animals. Ambrose
2015A

To that list can be added two similar recent reports in rat brains. Desjardins 2014., Viboolavorakul 2014

Age-lined reduced CD has also been found in rat kidney Kang 2002: Table 2, #7, in the subendothelium
of rat heart Iemitsu 2006, and in sponges placed in wounds of mice. Sadoun 2003 Thus there are 32
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reports of reduced levels of CD in various organ systems (and sponge inserts) of aged subjects
and animals.
Tables 3 & 4 present data from 7 reports showing reduced levels of AG factors in the
muscles of aged people and animals. Reduced levels of AG factors have also been found in the
brain (left parietal cortex) of aged rats Viboolvorakul 2014, in the heart (left ventricular wall) of aged
rats Iemitsu 2006, and in two reports of sponge implants in mice. Reed 1998, Sandoun 2003 Thus there are
11 reports of depressed levels of AG factors in various organs (or implants) of aged persons and
animals. These two sets of data (32 + 11) strongly suggest that reduced CD and lowered levels
of AG factors occur throughout the body in aged persons and in those old animals studied.
But the decline of CD and AG levels may not be uniformly expressed throughout the
body. To date, there is no documented concordance between muscle weakness and cognitive
decline in people, indicating either a differential decline in each organ system or that other
influences may affect aging in them. But correcting one influence (e.g., a reduced CD)
theoretically might benefit an aging brain or tired old muscles or both. Finally, mankind isn’t
helped by another theory on aging unless it offers tangible therapeutic options, which the
angiogenesis hypotheses on aging do. These options are discussed below at length in Part II.

Part II: Therapy of Muscle Weakness
7. Treatment of muscle weakness by therapeutic angiogenesis
Seeking to delay the decline in health associated with aging, millions of Americans
consume various vitamins and sundry supplements -- e.g., chondroitin sulfate & glucosamine,
hormones (testosterone, thyroxin), fish oil, ginkgo biloba, etc. Others have received periodic
injections of anti-aging agents -- e.g., B12, gonadal extracts, procaine HCl, etc. Theoretically, the
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process of aging should be slowed by certain biological agents. In 1974, Alex Comfort listed the
following: radioprotectants, protein synthesis inhibitors, anti-crosslinking agents, lysosome
stabilizers, antioxidants, immunosuppressants, and hormones. Comfort 1974 To these hypothetical
agents now might be added amyloid destabilizers, anti-telomerases and, according to this essay,
readily available ones -- e.g., recombinant angiogenic cytokines.
Attempts at therapeutic angiogenesis began over twenty years ago in animals with an
experimentally induced ischemic myocardium (e.g., by ameroid constriction of the left
circumflex artery) or ischemic skeletal muscles (e.g., ligation of femoral artery in hind limb). Banai
1991, Baffour 1992

First phase trials in patients with myocardial insufficiency soon followed. Henry

1998, Schumacher 1998

Studies in both animals and people, as noted below, have yielded practical

information about angiogenic factors (e.g., safe levels) applicable to the potential treatment of
muscle weakness of the aged -- hence the following brief review of cardiac and muscle studies.

7.1. Cardiac studies in animals & people
Lin et al. described cardiac sarcopenia in mice. Lin

2008

Myocyte numbers decrease while

there is increased fibrosis, accounting for the heart generally becoming thicker with age. Lin et
al. suggest that “cardiac sarcopenia may explain, in part, why elderly patients respond poorly to
cardiovascular events.”
In recent therapeutic studies on the heart, either of two classes of agents was introduced
into the ischemic myocardium of animals and later of people – the recombinant protein of
various growth factors or their genes (naked DNA as a plasmid or via a viral vector). Several
investigators have discussed these two approaches and have concluded that “protein therapy is
closer to practical use than gene therapy.” Simons 2000,

Post 2001

Most preliminary papers reported
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favorable results in treated patients. But a decade later, reviews concluded that neither of these
two approaches showed unequivocal clinical benefit in double-blind, randomized placebocontrol trials. Khurana 2005, Simons 2005 “Inadequate duration of exposure to the angiogenic agent”
may have limited its effectiveness. Gupta 2009 Another weakness in the clinical trials may have
been the assumption that a single factor would be effective. Zhang 2009 These two considerations
will be discussed later.

7.2. Skeletal muscle studies in animals
Ligation of a femoral artery in the hind limb of laboratory animals simulates lower leg
muscle weakness in older persons. Table 6A summarizes 5 such studies in mice, rats, and
rabbits showing increased hind limb vascularity ( CD) with angiogenic treatment. Table 6B
concerns 8 reports showing increased microcirculation (and healing) after the application of AG
factors in other experimental situations -- bone graft, wound repair, and sponge/gel implants.

7.3. Skeletal muscles studies in people
Post et al. noted the scarcity of clinical studies using AG factors in persons with
peripheral vascular disease. Post 2001 Nor have I found any reports examining the effect of
recombinant (r) angiogenic factors on the muscle weakness and sarcopenia of elderly persons.
The closest work is that by Lederman et al. showing the benefit of recombinant FGF-2 on
intermittent claudication (IC). Lederman 2002 Patients with limited walking tolerance caused by
infra-inguinal atherosclerosis received bilateral femoral artery infusions of three types: 1)
placebos on Days 1 & 30, 2) rFGF-2 on Day 1 & placebo on Day 30, 3) recombinant acidic FGF
on both Days 1 & 30. Exercise tolerance was measured using a standardized Gardner treadmill
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protocol. On Day 90 walking times in minutes were found to be increased from baseline values
in the three groups as follows: 0.97 min (5.32  6.29), 1.95 min (5:15  7.10), and 1.77 min
(5.81  7.58), respectively. Two infusions of r-FGF-2 thirty days apart (the 3rd treatment type)
appeared less beneficial than a single injection only because that group had a higher baseline
value (5.81 min.). The final assessment included 174 patients. Sixteen others were eliminated
because of adverse events, including renal abnormalities (proteinuria). The maximum tolerated
dose was 30 µg/kg. Higher levels induced acute hypotension. This study is valuable for
highlighting the placebo effect and identifying untoward effects from rFGF-2.

8. Angiogenic factors
Of primary concern for treating muscle weakness in the aged would be selecting a
therapeutic regimen. Simons concluded that in previous cardiac studies the choices of AG
agents had “little physiological rationale” but instead rested on the availability of certain growth
factors and the selection of those with less risk of side effects. Simons 2005 Again, useful
information for selecting a particular treatment may be gleaned from the past clinical and
laboratory studies -- notably, safe levels of these agents for people.

8.1. Single agents
Human trials to date have employed single agents – e.g., VEGF Vale 1999, Gibson 1999,
1999, 2003

, FGF-1 Schumacher 1998, and FGF-2.

Laham 1999, 2000, Unger 2000

Henry

These and other factors are

listed below, followed by brief abstracts of animal studies illustrating their use in therapeutic
angiogenesis.
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8.1.1. VEGF
Of the six members of this family, three (VEGF-A, -B, & -E) and PIGF (placental growth
factor) act preferentially on vascular endothelial cells. VEGF “maintains its position as the most
critical driver of vascular formation.” Yancopoulos 2000 VEGF-1 and VEGF-D  NC have the
strongest AG effect on skeletal muscles. Rissanen 2003
Takeshita et al. prepared rabbits with ischemia in one hind limb and injected a 500-5000
µg bolus of VEGF165 over one minute in the ipsilateral iliac artery on Day 10 after ligation of the
femoral artery. They found increased vascularity in the muscles of the treated leg by Day 30 but
no additional increase later. Takeshita 1994 Rivard et al. followed the same procedure using a 500 µg
bolus of VEGF165 and found increased capillary density on Day 40 after surgery in treated
rabbits, both young and old but somewhat less in the old ones. Rivard 1999: Fig 5G The latter authors
regarded VEGF as “the pivotal cytokine deficiency responsible for impaired angiogenesis.”

8.1.2. FGF
Of the 23 or so members of this group, FGF-1 (acidic FGF, aFGF) and FGF-2 (basic
FGF, bFGF) are prototypes which are “preferentially implicated in angiogenesis.” Friesel 1995,
2001

Post

The most studied member, bFGF, has a broad spectrum of target cells – endothelial cells,

smooth muscle cells, and fibroblasts. Friesel 1995
Baffour et al. examined bFGF in the ischemic hind limb rabbit model. Three groups of
rabbits received various intramuscular injections daily for 14 days – 17 rabbits being saline
controls, 15 receiving 1µg bFGF, and 15 receiving 3µg bFGF. Day 14 angiograms of the treated
limbs showed CDs in the three groups, respectively, of 36 ±10, 69 ± 15, and 108 ± 7. Baffour 1992
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These data plus related work by Yang et al., Witzenbichler at al., and others are listed in Table
7A. Yang 1996,

Witzenhichler 1998

8.2. Agents in synergism
Various investigators have assumed that the clinical administration of a single AG factor
(e.g., VEGF) would be ineffective, since several or many may be necessary for a coordinated
angiogenic response. Cao 2003,

Zhang 2009

This synergism has been observed in several in vitro

studies. Endothelial cells cultured within three-dimensional collagen gels and treated with
VDGF and bFGF showed a synergistic effect on proliferation and cord formation – as additive
effect greater than that of each agent alone. Pepper 1992, Goto 1993 Other examples of synergism are
given below.

8.2.1. Angiopoietin
There are the four members of this family. Generalizing from many studies,
Yancopoulos et al. wrote that Ang-1 acts synergistically with VEGF to promote vessel stability,
while Ang-2 has the opposite effect. Yancopoulos 2000 Lloyd et al. cautioned that the ratio present
may be crucial. Lloyd 2003
Peirce et al. examined the coordinated role of VEGF165 and Ang-1 in dorsal skinfold
window chambers surgically positioned on the backs of rats five days before Day 0 of the study.
Slow release alginate beads contained either VEGF, Ang-1, or neither agent. A single bead was
inserted in the visual field of each chamber on Day 0 and replaced on Day 7. The chamber with
a VEGF bead on Day 0 and control beads on Day 7 showed increased CD on Days 7 and 14 but
not 21. The chamber with VEGF bead on Day and Ang-1 on day 7 showed increased CD on
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Days 7, 14, and 21, thus indicating that Ang-1 “promote[d] vessel stabilization and maturation.”
Peirce 2004

8.2.2. Platelet derived growth factor.
There are three isoforms of PDGF: AA, AB, and BB. In an ischemic hind limb model in
rats, Zhang et al. found that PDGF-AB + FGF-2 yielded stable capillary growth, while PDGFAA + FGF-2 did not. Zhang 2009
Cao et al. used a Matrigel pellet model, in which heparin-Sepharose beads containing one
or two factors were inserted subcutaneously into mice and after two weeks retrieved and
examined microscopically for vessel formation. Cao 2003 They found that PDGF-BB + FGF-2
elicits angiogenesis greater than the sum of the separate effect of both agents, while PDGF-BB +
VEGF produced only a slightly additive effect to that of either one alone. Since endothelial cells
delineate the capillary lumen, while mural cells (pericytes and smooth muscle cells) stabilize it,
the authors inferred that these two separate functions are controlled by different AG factors – the
former by FGF-2 or VEGF and the latter by PDGF. The above four reports show that stable
angiogenesis was produced with the appropriate combinations of factors.

8.3. Further considerations
Most clinical trials of the past several decades have employed only one agent. Single
factor therapy for treating myocardial insufficiency has occasioned few or no complications. Henry
2000, Celletti 2001, Epstein 2001

But Yancopoulos et al. and other investigators have warned that the

administration of “a single growth factor to reconstitute a vascular bed is somewhat naive and
even misguided.” Yancopoulos 2000,

Henry 2000

Here the authors may have had in mind VEGF’s
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original name, “vascular permeability factor,” the risk of internal bleeding, and the stabilizing
effect of Ang2 on VEGF. While this risk must be kept foremost in mind, an additional
consideration explained below may qualify the above warning in the case of muscle weakness of
the aged.
In older animals and people the levels of certain angiogenic factors are reduced in various
tissues (muscle, brain, heart), but there is no evidence that all factors involved in producing the
coordinated response of angiogenesis are reduced equally. Returning a deficient one to the
earlier, youthful level might be sufficient if other participating factors are still available in tissue
sites. Based on this assumption and in lieu of the few complications reported in numerous
clinical trials with VEGF and FGF, replacing a single waning factor might be safe and effective
in ameliorating general muscle weakness of old age. But this consideration still acknowledges
the theoretical risk from long term treatment – i.e., longer than past clinical trials.

9. Various routes for therapeutic angiogenesis
Studies aimed at returning AG factors in muscles to normal, healthy levels would likely
continue for many years – for the rest of an aged person’s life. Dor 2002, Annex 2005, Ferrara 2005, Gupta 2009,
Roy 2010

If therapeutic angiogenesis were found to be effective in preliminary trials, then the wide

spread use of this method would be most feasible if it involve the self-administration of the AG
factor. Intravenous and intramuscular routes are not convenient and disliked by many subjects.
Agents ingested would be destroyed through acid/enzymatic breakdown in the gastro-intestinal
tract. Alternative routes involving absorption via the nose, lung, cheek, or tongue avoid the GI
destruction and first pass metabolism in the liver and would be preferable to injections by most
subjects. (Ophthalmic, vaginal, and rectal routes are not considered here.)
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An obstacle at the four alternative sites is the absorption of macromolecules across lipidrich epithelial cell membranes into the circulation. Such absorption is inversely related to a
protein’s molecular weight – i.e., being less for large proteins, such as bFGF (17 kDa) and VEGF
(42 kDa). Molecular weights are given for most of the AG factors noted below. Ways of
overcoming the weight problem are discussed in Section 10.1.

9.1. Nose
Some sense of the absorption of various size macromolecules across mucous membranes
into the circulation can be gleaned from the following examples. Intranasal (i.n.) administration
of oxytocin (1.0 kDa) led to its appearance in the plasma for up to two hours. Gossen 2012, Striepens 2013
Numerous investigators have determined blood levels of immunoreactive insulin given by this
route. Pontiroli 1989: Table 1 Insulin (5.8 kDa) administered i.n. reduced blood glucose levels, thus
inferring the hormone’s bioavailability in the systemic circulation. Pontiroli 1992 In normal subjects,
an i.n. spray of insulin plus Na glycogluconate produced a serum insulin level 4-times higher
than a spray with insulin alone. Pontiroli 1987: interpr. from Fig. 1 Thorne et al. found rising levels of [125]insulin-like growth factor-1 (7.65 kDa) in the blood of rats 23 minutes after i.n. treatment. At 21
minutes the level of the above ILGF-1 was 0.48 nM in the blood and 0.15 nM in the deltoideus
muscle. Thorne 2004: Table 1 Vitkun et al. delivered interferon β-1a (20 kDa) by nasal spray to male
subjects and found 20% bioavailability in blood samples. Vitkun 2004 The possible administration
of AG factors (17-45 kDa) intranasally to senile dementia patients was raised in two earlier
papers. The use of a tobacco-free snuff was suggested there. Ambrose 2013, 2015A

9.2. Lungs
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The potential advantages of pulmonary delivery of macromolecular proteins are the
lungs’ large absorptive area, extensive vasculature, easily permeable membrane, and low
enzyme activity Patton 1992,

Liu 1993

Wigley et al. administered insulin to diabetic patients during a

5-minute nebulization period and found that 10% had been absorbed into the plasma. Wigley 1971
Liu et al. reported that intratracheal instillation into rat lungs of the sodium dimer (11.6 kDa) or
the zinc hexamer (34.8 kDa) of insulin led to the drug’s absorption as reflected in reduced blood
glucose levels. The exact form of insulin (monomeric or multimeric) in the blood was not
determined. The effect on blood glucose levels was similar whether the insulin preparation was
entrapped in or merely accompanied by liposomes. Aerosol administration was judged to yield
“comparable” results. Liu1993

9.3. Buccal cheek
The buccal mucosa is less permeable than the nasal mucosa, but most elderly subjects
would probably prefer the former as a therapeutic route. Merkle 1991 Three types of adhesive buccal
vehicles provide intimate contact with mucous epithelium: tablets, viscous gels, and patches.
Merkle 1991

Boddie et al. employed buccal tablets made of muco-adhesive polymers, which protect

against degradation by peptidases in the saliva. Boddie 1990
I have not found articles about enhancing absorption of AG factors with various
adjuvants, but this approach is suggested by positive results of studies on other large molecules.
Buccal adjuvants have included bile acids, fatty acids (e.g., myristate), and sugar esters. Merkle 1991
Nakada et al. reported that deoxycholate, turoglycocholate, quillajasaponin, myristate, and sugar
esters promoted absorption of human calcitonin (3.4 kDa) via buccal mucosa of rats. Nakada 1988
Merkle et al. cited studies with the above adjuvants showing increased buccal and sublingual
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absorption of the following proteins: oxytocin (1 kDa), calcitonin (3.4 kDa), insulin (5.8 kDa),
interferon (17 kDa), etc. For example, 5% Na glycocholate added to insulin via buccal route 
25.5% of bioefficiency of the same dose of insulin given i.m. Aungst 1989

9.4. Tongue
The sublingual mucosa of the tongue underside is only 100-200 µm thick, has fewer cell
layers than the buccal mucosa, and is non-keratinized – all favoring better absorption. Shojaei 1998
In 1972 Sister Philomena Earle prepared 10 mg, I inch diameter tablets containing insulin HCl
(5.8 kDa) along with a binder and vasodilator (neither defined) for placement on or under the
tongue. Using the tablet, she noted “a definite hypoglycemic reaction within 10 minutes” and a
blood glucose estimate of 48 mg/ml. Earle 1972 No baseline data were provided. Aungst et al.
determined the absorption efficiency of insulin given by different routes to that by IM injection.
The rank order of absorption was rectal >nasal >buccal >sublingual. Inclusion of Na
glycocholate to the insulin greatly increased absorption with the nasal route being the highest at
46.8% and sublingual being 12%. Aungst 1988

10. Other issues in therapeutic angiogenesis
Of theoretical concern is whether exogenously administered AG factors could correct a
local deficiency in muscles. Affirmative evidence is present in Table 6A, which outlines five
reports showing increased CD in the ischemic hind limbs of lab animals injected IV, IM, or
subcutaneous with VEGF or bFGF. At issue is whether AG factors administered via the
alternative routes (e.g., nasal, etc.) can pass into the circulation for access to distant muscles.
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10.1. Absorption of AG factors
In spite of their large size, perhaps AG factors (17-45 kDa) can be modified to become
more transferable without losing funtionality. Addition of methyl groups renders large molecule
more lipophilic and thus more absorbable. Katrusiak 2011,

Gazdik 2014

Surfactant enhancers in the form of various bile salts, etc. may facilitate this transfer.
Gordon 1985, Aungst 1988, Wearley 1991, Lambert 2007

For example, Daugherty et al. administered recombinant

methionyl human growth hormone (ca. 20 kDa) via the nasal mucosa of rats. The bioavailability
in blood was 1% but rose to 7-8% in combination with bile salt sodium glycocholate. Daugherty 1988
But these permeation enhancers may cause irreversible damage to mucosal cells. Gordon 1985
Polycationic materials (poly-L-arginine/lysine) and chitosan may also enhance absorption
of macromolecules. For example, in rat nasal studies, Miyamoto et al. found that adding poly-Larginine to a recombinant human granulocyte colony stimulating factor (rhG-CSF = 20 kDa)
increased its bioavailability to 10%. Miyamoto 2001 However, such enhancers may also be toxic to
mucosal epithelium.

10.2. Sustained treatment
Since the lesser ailments of old age developed over many years, it seems unlikely that
single bolus therapy could be effective. Treatment may need to be continuous and life-long.
Many months may be required before beneficial clinical results become evident. In human trials
sustained release delivery of an agent may be achieved with multivesicular liposome
(DepoFoam). Angst 2006 Alginate capsules and nanoparticles have been used in various studies.
Strand 2002, Peirce 2004, Roy 2010

The half-life of a protein in the circulation is determined by plasma proteases. McGonigle 2012
Takashita et al. reported unpublished data of N. Ferrara et al. listing the half life of VEGF as less
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than six minutes. Takashita 1994: 667 Protection of exogenous therapeutic agents can be obtained
using liposomes and certain polymers. Boddie 1990 According to Katre et al., the free form of
Insulin-like Growth Factor-1 survived in blood for less than one day but when incorporated into
liposomes was sustained there for 5-7 days. Katre 1998

10.3. Side effects
Treatment continued over many years raises the threat of untoward mitogenesis inducing
“angiogenic diseases” -- e.g., tumor growth, diabetic retinopathy, polyarthritis, psoriasis, etc. Jain
1997, Epstein 2001, Carmeliet 2003

Also, there has been concern that angiogenic therapy may promote the

growth and rupture of atheromatous plaques leading to angina and myocardial infarcts.
1993, Kornowski 2000, Simons 2000, Celletti 2001, Moulton 2001

Flugelman

Recognizing untoward side effects is one purpose

of clinical trials. Finding ways to avoid and correct them is the later challenge.

11. Summary of Part II
In contrast to Part I of this essay, which focused on age-linked decline of AG factors
with aging, there are the numerous studies in regular (not aged) mice and rats showing that levels
of endogenous VEGF are increased in the immediate areas of experimentally generated cerebral
infarcts or surgically induced focal cerebral ischemia. These studies were identified in references
#130-138 in an earlier paper. Ambrose

2015A

Thus under some circumstance, angiogenesis is

naturally induced locally.
There is a growing consensus that the “induction of angiogenesis is a promising
therapeutic approach … to improving vascular function … in aging patients.”

Lähteenvuo 2014.
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This expectation has not yet been realized for relieving weakened muscles of aged persons but
has been amply demonstrated in laboratory animals. Various angiogenic factors administered to
ischemic hind limbs of mice, rats, and rabbits have produced increased vascularity in the muscles
there (Table 6A). Local application of AG factors to bone transplants, surgical wounds, and
inserted sponges have likewise led to increased local vascularity (Table 6B).
The most impressive support to the idea of therapeutic angiogenesis has been in the
brain. Discussed elsewhere are the clinical studies by Harry S. Goldsmith, who transposed the
intact pedicled omentum from persons with Alzheimer’s disease (AD) onto the surface of their
brain. Ambrose

2015A, Goldsmith 2014

These pedicles, which contain high levels of VEGF, release this

factor onto the cerebral surface, where it is absorbed into the parenchyma. Zhanga 1997 Goldsmith
recently reviewed 25 such operations on advanced AD patients and reported that six showed no
improvement, ten showed slight improvement, and “nine demonstrated marked cognitive
increases.” Goldsmith 2014 Of concern here is whether the positive results Goldsmith obtained in
some AD patients with omentum grafts can be replicated for muscle weakness of old age by the
administration of angiogenic factors.
As discussed earlier in Part I, muscle weakness from age-associated sarcopenia may have
one or more possible causes -- 1) waning angiogenesis, 2) the temporal decline of muscle stem
cells capable of “life-long maintenance and repair of myofibrils,” Carlson 2008 and 3) a deficiency
of certain hormones (e.g., testosterone). In spite of an incomplete understanding of the interplay
of these possible causes, evidence supports considering the treatment of the muscle weakness of
old age with therapeutic angiogenesis.
Edelberg and Reed began an article in 2003 with “Angiogenesis is impaired in aged
tissues.”

Edelberg 2003

Another review like the present essay reaffirming this well documented
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observation would seem unnecessary except for the fact that therapeutic angiogenesis has yet to
be pursued in the relief of the lesser ailments of old age and the senile dementias.

12. Conclusions
In this essay, old age is viewed as a deficiency state in which muscle weakness and
memory loss may be due in part to a reduced microcirculation secondary to the age-linked
decline of angiogenic factors. Waning stem cells and lower hormone levels may also exert a
weakening effect on muscles via diminished angiogenesis. Senile dementias may be a long term
consequence of the decline of angiogenic cytokines in the brain along with other possible
influences. This general decline is analogous to that of certain hormones whose blood and tissue
levels fall with age. Again, other influences besides a waning angiogenesis may also contribute
to aging. But correcting one influence (e.g., a reduced CD) may delay symptoms and signs of
aging.
Therapeutic angiogenesis with recombinant AG factors seems an appropriate treatment to
be considered for the lesser ailments of old age and also senile dementias and would be
equivalent to administering testosterone, thyroxin, etc. to persons with the corresponding
hormonal deficiencies. The beneficial effect of these agents may continue up to the time when
other pathologies intervene, leading to death.
End

29
FOOTNOTES
Footnote #1. Riddle et al. summarized three decades of studies on age-related changes in
cerebral capillary density in human subjects and rats. They listed 14 reports of decreases and 7
of no decreases. Riddle 2003 An explanation of the latter results may be tissue shrinkage in aged
brains, which was discussed in a previous paper. Ambrose 2015
Footnote #2. Notch refers to receptor proteins in the wall of cells enabling two adjacent
ones (e.g., myogenic stem cells) to interact mechanically. The name derives from notches in the
wings of mutant fruit flies. Various notched phenotypes were correlated with mutant loci in the
flies’ chromosome. Morgan 1917 A gene homologous to the Notch gene in Drosophila was found in
patients with lymphoblastic leukemia. Ellisen 1991 The name Notch has subsequently been applied
to a genetic pathway system later found in myogenic precursor cells of higher animals.
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Table 1. Reduced Capillary Density in Muscles of Young vs. Aged Persons
Young

Aged

24 ± 1 yrs.
308 ±16
328 ± 19

64 ± 1 yrs.
228 ± 13
248 ±12

2. Proctor 1995, Table 3
vastus lateralis
-- capil./mm2
-- capil. contact/fiber IIA & IIB

21-30 yrs.
419 ± 87
5.0 ± 0.9

51-62 yrs.
390 ± 41
3.9 ± 0.8

3. Chilibeck 1997, Table 3
lateral gastrocnemius
-- capil./mm2

25.9 yr., mean
295 ±105

66.9 yr., mean
245 ± 50

4. Frontera 2000, Table 4
longitudinal study, men (∆ 12 yrs)
-- capil./fiber

1985-6
1.39 ± 0.21

1997-8
1.08 ± 0.1

5. Ryan 2006, Fig 2D (ex)
vastus lateralis
-- capil./mm2 vs. Type 1 fibers

19-25 yrs.
240

62-72 yrs.
200

1. Coggan 1992, Table 3
lateral gastrocnemius
-- capil./mm2, male
-- capil./mm2, female
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Table 2. Reduced Capillary Density in Skeletal Muscles of Young vs. Aged Animals
1. Haidet 1991, Table 6
Beagle dogs, cap/µm2
-- gastrocnemius
-- semitendinosus
-- triceps
2. Degens 1993, Fig.4 (ex) *
rat plantarus
-- capil./mm2
3. Rivard 1999, Fig. 5 (ex) *
-- mice hind limb, capil./mm2
-- rabbits hind limb, capil./mm2
4. Leosco 2007, Fig. 3
rat hind limb, capil./mm2
-- untrained
-- trained

Young

Aged

2-3 yrs.
886 ± 49
895 ± 41
959 ± 47

10-14 yrs.
718 ± 31
658 ± 31
805 ± 52

5 mo.
1000

13 mo.
850

25 mo.
700

12 wks.
710
6-8mo
170

2 yrs.
350
4-5 yrs
130

4 mo.
590
750

24 mo.
300
475

* Data in some figures have been extrapolated from figures, as indicated by (ex).

52
Table 3. Reduced Angiogenic Factors in Muscles of Young, Aged, & AD Subjects
1. Drubaix 1998, Figs. 4,5 (ex )
ng/mg DNA of saphenous vein wall
-- bFGF
-- PDGF
2. Solerte 2002, abstract
VEGF released, pg/ml
-- from monocytes
3. Croley 2005, Fig. 2A (ex)
VEGF/B actin ratio, after exercise
-- females gastrocnemius muscles

Young
20-40 yrs.
180
70

Aged
41-60 yrs.
70
45

healthy (yrs. not stated)
296

61-82 yrs.
50
30
AD & VAD
125

22-28 yrs
7.6

60-85 yrs
3.2

4. Ryan 2006, Fig. 4,5 (ex)
vastus lateralis in men
19-25 yrs.
-- VEGF 18s mRNA, at rest
1.0
-- VEGF 18s mRNA , 4 hrs after exercise 3.4
-- VEGF protein, at rest
1.05
-- VEGF protein, 4 hrs after exercise
1.15

62-72 yrs.
0.4
1.8
0.55
0.9

* Data in some figures have been extrapolated from figures in text, as indicated by (ex).
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Table 4. Reduced Angiogenic factors in Skeletal Muscles of Young vs. Aged Animals
Young
Aged
1. Rivard 1999, Figs. 8A&C
VEGF protein in ischemic muscle of rabbits 12 wks.
2 yrs.
-- Western blot, Fig. 8A
young level
reduced
-- immunostaining, Fig. 8C
young level
reduced
2. Wagatsuma 2006, Fig. 2 (ex)
gastrocnemius muscle of mice
-- VEGF

2.5 mo.
1.0

3. Swift 1999, Table 1
muscle wound homogenates of mice
2-3 mo.
-- VEGF … before injury/wound
not detectable
day 5
116
day 7
84
-- FGF-2 … before injury
27
day 5
362
day 7
407

22 mo.
0.7

-43
49

22-24 mo.
65
253
263
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Table 5. Physiological Angiogenesis in Muscles
5A. PHYSICAL EXERCISE … ↑ = increase, ↓ = decrease … G20 = ca. age 20, G60 = ca. age 60
-- People … 15 studies … aerobic training and muscles
Andersen 1975, 1977 … ↑ CD by 50%
Brodal 1977 … ↑ CD … corrected for fiber shrinkage: 305  425
Ingjer 1978, 1979 … female … ↑ CD: 1.39  1.79 (<0.005)
Denis 1986 … ↑ CD: G20: 316  396 … G60: 308  409
Hather 1991 … ↑ CD
Coggan 1992 … ↑ CD … less so in aged males & females
Hepple 1997 … ↑ CD
Richardson 1999 … ↑ VEGF/18s: 0.38 ±0.04  16.9 ±6.7 … no effect with βFGF mRNA
Gustafsson 1999 … 3x ↑ VEGF & VEGF mRNA … FGF not increased
Gustafsson 2001, 2002 … 2-3x ↑ VEGF & VEGF mRNA
Ryan 2006 ... ↑ VEGF/18s … less so in aged
Gavin 2007 … ↑ CD, ↑ VEGF … lesser increase in aged
-- Animals … 6 studies
Unger 1979 rats … swimming  ↑ myocardial capillary cell walls … no signif. ↑ in aged rats
Adolfsson 1981 rats … ↑ CD … skeletal muscle … less so in old rats
Breen 1996 rats … ↑ VEGF, ↑ TGF-β, ↑ βFGF … skeletal muscle
Gavin 2000 rats … ↑ receptor Flt for VEGF mRNA … skeletal muscle
Amaral 2001 rats … ↑ CD … VEGF neutralizing Ab blocked angiogenesis … skeletal muscle
Lloyd 2003 rats … ↑ CD, ↑ VEGF … skeletal muscle
5B. ELECTRICAL STIMULATION -- Animals only … 10 studies in muscles
Brown 1976 rabbits … ↑ CD
Hudlicka 1982 rabbits … ↑ CD
Hang 1995 rats … 6x ↑ VEGF mRNA
Annex 1998 rabbits … 3x ↑ VEGF
Roca 1998 rats … 3x ↑ VEGF mRNA … no change in βFGF or TGF-β1
Skorjanc 1998 rabbits … ↑ CD, ↑ VEGF mRNA
Kanno 1999 rats … ↑ CD, ↑ VEGF … ischemic hind limb
Milkiewicz 2001 rats … ↑ VEGF
Verhaeg 2001 rats … ↑ CD
Hudlicka 2002 rats/rabbits … ↑ CD, ↑ VEGF
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Table 6. Ischemic Hind Limbs, Grafts, Wounds, & Sponges Treated with Various AG Factors
6A. Ischemic hind limb model … 5 studies … ↑ = increase
-- Takeshita 1994, 1995 in rabbits … VEGF, IV bolus 1x  ↑ CD
-- Rivard 1999 in rabbits, mice … VEGF, IV bolus 1x  ↑ CD
-- Baffour 1992 in rabbits … rh bFGF, IM qd x2 wks  ↑ CD
-- Yang 1996 in rats … bFGF, subQ pump x 14 days  ↑ CD
-- Witzenbichler 1998 in rabbits … rh VEGF-C, IV bolus x1  ↑ CD

6B. Wounds (full thickness skin, sponge/gel implants, bone graft) … 8 studies
-- Eppley 1988 in rabbits … bone grafts … bFGF  ↑ vascularity & healing
-- McGee 1988 in rats … skin wound … bFGF  “modest” ↑ healing
-- Beck 1990 in pigs … skin wounds … rhTGF-β1  ↑ blood flow
-- Greenhalgh 1990 in mice … skin wounds … rbFGF & rPDGF-BB  ↑ CD
-- Tsuboi 1990 in diabetic mice … skin wounds … βFGF  ↑ CD & healing
-- Puolakkainen 1995 in aged rats … skin wounds … TGF- β1  ↑ CD & healing
-- Thompson 1988 in rats … gelatin sponges in skin with aFGF  “significant angiogenesis”
-- Dellian 1996 in mice … gel in skin chamber with VEGF & βFGF  ↑ CD

aFGF = heparin binding growth factor
PIGF = rPDGF-BB = platelet derived growth factor
qd = every day
rh = recombinant human
VEGF = vascular endothelial growth factor
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